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Abstract
Background: In some countries the misuse and diversion of prescribed opioid analgesic is increasing considerably,
but there is no official data regarding the situation in Colombia. The aim of this study was to identify all dependent
to opioid analgesics legally prescribed patients that were treated in a University Hospital in Medellin, Colombia
during 4 years and to characterize this population.
Methods: Observational study in a University Hospital in Medellin, Colombia, searching for patients with ICD-10
codes related with opioid related disorders, adverse events or pain and treated between January 2011 and
December 2014.
Results: Sixty patients with opioid dependence according to DSM-IV criteria were found from 3332 clinical charts
reviewed. The median age was 43 years. Although all patients met the DSM-IV criteria, 33 % of patients were wrongly
diagnosed by other ICD-10 codes. Almost all patient (88 %) initiated opioids after medical prescription although the
adherence to pain scale was low (25 %). The median time of consumption was 48 months. Tramadol was the opioid
more frequently used by patients, followed by morphine and oxycodone. A statistically significant higher consumption
of other psychotropic substances was observed in male than female (P = 0.005 by Fisher’s test). After be diagnosed,
55 % of patients gone a methadone-based replacement therapy.
Conclusion: Legally prescribed opioid dependence was belatedly diagnosed in 60 patients in a University hospital,
after prolonged use of drugs to treat chronic pain and with low adherence to pain scale or guidelines. This is the first
report in Colombia.
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Background
The opioid analgesics are essential medications in the
management of acute and chronic pain [1]. Although
the effectiveness of opioid therapy to improve chronic
pain is questionable [2], the successful pain relief may
require high doses and longtime usage of opioids,
increasing the risk of abuse and dependence disorders
induced by these drugs [3].
Abuse of legally prescribed opioids could be potenti-
ated because these drugs are broadly available, are man-
ufactured by well-recognized pharmaceutical companies,
and there is a perception of safeness during the use of
opioids by the people, minimizing its addictive potential
[4]. The medical dilemma is simple, physicians need opi-
oid drugs as treatment but there is an unequivocal risk
of abuse and dependence that should be considered and
minimized.
In some countries, the abuse and diversion of pre-
scribed opioid analgesic is growing since two decades
ago [5]. In United States, 25 million people consumed
legal opioids for nonmedical uses between 2001 and
2011 [6]. More than 10 % of the admissions for treat-
ment in opioid abuse in this country and 16,651 deaths
were attributed to prescription opioid drugs [6]. Cur-
rently, in Australia and New Zealand the opioid abuse
and dependence is at least three fold more common
than similar disorders induced by heroin [1, 4, 6].
However, in Colombia there are no official statistics of
the misuse of prescription opioid medications, and appar-
ently, in contrast to other countries it is not considered as
a real problem by government agencies. This lack of data
contradicts the increasing clinical observations of new
patients treated by dependence to legally prescribed opi-
oids in our country. The aim of this study was to identify
all patients with opioid analgesic dependence that were
treated in a University Hospital in Medellin, Colombia
during 4 years and to characterize this population.
Methods
Study
Retrospective observational study reviewing the clinical
chart of all patients treated for dependency to legally
prescribed opioids in the University Hospital (Hospital
Universitario San Vicente Fundacion) in Medellin,
Colombia between January 2011 and December 2014.
Sample size and population
As there were neither reference studies nor government
statistics, a non probabilistic sampling was used. To iden-
tify the cases, a systematical review of all registries of out-
and inpatients reported by the University Hospital was
done, looking for the following ICD-10 codes potentially
related with dependence to legally prescribed opioids: (a)
opioid related disorders: opioid abuse, (b) opioid related
disorders: opioid dependence, (c) opioid related disorders:
with withdrawal, (d) opioid related disorders: with other
opioid-induced disorder, (e) opioid related disorders, un-
specified, (f) acute pain, (g) chronic intractable pain, (h)
other chronic pain, (i) pain, unspecified, (j) poisoning:
other opioids, and (k) opioids and related analgesics: ad-
verse effects.
All the clinical records of the adult patients (aged 18
or older) associated with at least one of the ICD-10
codes specified above and treated in University Hospital
during the period of the study, were reviewed by some
of the authors (all physicians) to select the cases which
fulfilled the DSM-IV diagnostic criteria for opioid de-
pendence, which includes three or more of the follow-
ing, occurring at any time in the same 12-month period:
(a) tolerance, (b) withdrawal, (c) the substance is often
taken in larger amounts or over a longer period than
was intended, (d) there is a persistent desire or unsuc-
cessful efforts to cut down or control substance use, (e)
a great deal of time is spent in activities necessary to ob-
tain the substance or recover from its effects, (f ) import-
ant social, occupational, or recreational activities are
given up or reduced because of substance use, (g) the
substance use is continued despite knowledge of having
a persistent or recurrent physical or psychological prob-
lem that is likely to have been caused or exacerbated by
the substance [7].
The exclusion criteria included illegal opioids depend-
ence and mixed disorders (i.e., consumption of illegal
and legal prescribed opioids).
Data collection
For the data collection a questionnaire was designed ac-
cording to the study variables in Google Forms. Three of
the trial physicians reviewed all the clinical records with
the pre-established ICD-10 codes, and fulfilled a ques-
tionnaire for every patient.
Statistical analysis
A simple descriptive analysis for all variables was per-
formed. Discrete data were summarized as percentage
while continuos ones were presented as median with
range from minimum to maximum. To determine the
relationship between two categorical variables, the data
of nominal variables as demographic variables (i.e.,
marital status, origin, education level, etc) or consump-
tion patterns (i.e., number of patients consuming opioid
for diversion, self-medication, etc), were compared be-
tween genders by Chi-square independence test or
Fisher’s exact test (when the expected number of sub-
jects in a single cell was less than 5). The information
was processed with the statistical package Instat®
(Graphpad, USA).
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Results
A total of 3332 records were obtained from the University
Hospital database, both inpatient and outpatient, since
January 2011 to December 2014. A total of 60 patients ful-
filled the DSM-IV criteria for opioid dependence.
The patients and their main demographics characteris-
tics distributed by gender are shown in Table 1. The
population studied was equally distributed between male
and female with 30 patients in each case, and there were
no statistically significant differences comparing all
demographic variables by gender (P-value >0.11 by Fisher’s
exact test). The median age was 43 years, ranging from 18
to 87 years old. In general, the most frequent kind of
patient included was single, widower or divorced, from
the metropolitan area, employed with some level of
education.
Table 2 summaries the clinical characteristics related
with dependence to legally opioids in the 60 patients
studied. It should be noted that only two thirds of
patients involved were diagnosed with opioid related
disorders, meaning that up to 33 % of patients with
DSM-IV criteria to dependence to opioids were undiag-
nosed or clinically treated by other reasons without
suspicious of this disorder. Additionally, almost all of
patients (88 %) initiated on opioids by a medical pre-
scription to treat any type of pain, although the de-
scription of the use of a pain scale was minimum
(25 %) in our population. In this context, could be not
surprising that the perpetuation of the opioids misuse
was related with self-medication of these drugs mainly
justified by an apparent pain. Only 4 of 60 patients
(7 %) had an oncologic diagnosis.
Regarding the characteristic of the consumption, the
more frequently used opioid by patients involved was
tramadol, followed in order by morphine, oxycodone
and others (Fig. 1). One opioid was used by 23 sub-
jects as single drug related to the dependence, the
remaining persons received or rotate by multiple opi-
oids. The more common rotation of drugs was using
morphine and tramadol (6 of 37 patients, 16 %). The
median time of consumption was 48 months, ranging
from 1 to 240.
The consumption of other psychotropic substances as-
sociated with opioid dependence was found in 15 (25 %)
male patients and 4 (7 %) female patients, with statistical
significance (P = 0.005); in general, 37 % consumed to-
bacco, 21 % alcohol, and 16 % other psychotropic sub-
stances not specified (Table 3). It should bear in mind
that the data from 11 (18 %) patients was missing.
Among the patients with opioid misuse, 32 (55 %) had
been started on replacement therapy with methadone
after months or years of diagnosis of opioid dependence
by DSM-IV criteria, and 24 (40 %) patients had under-
gone other unspecified treatment. In 1 case (2 %) no
treatment was started, and there was no any treatment
information for other two patients (3 %).
Finally, DSM-IV criteria more frequently found were
that the substance was often taken in larger amounts or
over a longer period in 59 patients (98 %), followed by
tolerance in 57 cases (95 %), withdrawal in 57 users
(95 %), an unsuccessful persistent desire to cut down the
misuse in 54 subjects (90 %), and a great deal of time is
spent in activities necessary to obtain the substance or
recover from its effects just in 30 patients (50 %), the
Table 1 Demographic characteristics of the population by gender
Variable Options Male
N = 30 (%)
Female
N = 30 (%)
Total
N = 60 (%)
P-value
Age 18–60 years old 30 (100) 26 (87) 56 (93) 0.11a
>60 years old 0 (0) 4 (13) 4 (7)
Marital Status Single, widowers or divorced 14 (47) 15 (50) 29 (48) 0.89b
Married & cohabiting 13 (43) 13 (43) 26 (44)
No data 3 (10) 2 (7) 5 (8)
Origin Metropolitan Area 18 (60) 15 (50) 33 (55) 0.73b
Outside The Metropolitan Area 6 (20) 7 (23) 13 (22)
No data 6 (20) 8 (27) 14 (23)
Occupation Employee 19 (63) 23 (77) 42 (70) 0.50b
Unemployed 7 (23) 5 (17) 12 (20)
No data 4 (14) 2 (6) 6 (10)
Education Level Undergraduate 15 (50) 19 (63) 34 (57) 0.35b
Postgraduate 7 (23) 3 (10) 10 (16)
No data 8 (27) 8 (27) 16 (27)
aP-value by Fisher’s exact test
bP-value by Chi-square test
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remaining were present in less than 46 % of population
studied.
Discussion
The opioid analgesic dependence (OAD) is a well-
recognized health problem in many countries [4], it is
even considered an epidemic problem [8, 9]. In United
States, the number of opioid overdose deaths are similar
to number of deaths from car accidents [10]. Here, we
described the first observational study performed in
Colombia corroborating that OAD is also a real and
problematic situation.
Although there is no official data, it has not scape our
attention that our study performed in just one high spe-
cialized hospital in Medellin, Colombia, were more than
enough to detect 60 patients during 4 years, that is ap-
proximately 15 cases per year. This finding supports the
importance to perform a national surveillance including
multiple medical centers to identify the prevalence of
this disease.
It has been described that most of the patients with
OAD initially obtained the drug misused from a phys-
ician, but then the patient abuse of this formulation,
whether looking for an euphoric effect or for avoiding
the withdrawal symptoms [11]. In our study, we de-
scribed a similar behavior, that is 88 % of patients started
on opioids by a medical prescription to treat any type of
pain with a low adherence to pain guidelines or scales,
highlighting the utility of education to improve the ad-
herence to national guidelines, better methods for diag-
nosis and monitoring, and stronger laws in Colombia
that help control this problem with high risk to increase
in short term.
Demographic characteristics of our population were
closer to other studies [12–14], that is OAD are more
common in median age patients, without difference by
gender, and being initially prescribed for non-cancer
pain management. This situation is probably showing
the increasing use of opioids for acute and chronic non-
cancer pain and the lack of a stepped pain treatment
and the fail to follow the current recommendations as
well [15].
In other countries, hydrocodone is currently topping
all prescriptions of prescription opioids [8]. Unlike those
statistics, tramadol was the initial and most frequent
prescribed and misused opioid. This result is similar to
the reported by Zhang et al., describing that the long
period of use and/or high doses of tramadol may be one
important risk factor of abuse even for those with no
prior drug abuse [16]. Tramadol is a weak mu opioid re-
ceptor agonist and also possesses catecholamine re-
uptake inhibitor property [17]. It has been postulated
that M1 metabolite of the drug mediates these actions.
Mu receptors are involved in the euphoric symptoms
Table 2 Clinical description of the characteristic related with
dependence to legally opioids observed in the 60 patients
studied
Description Yes (%) No (%) No data (%)
Number of patients with opioid related
disorders according to ICD-10 codes
(F11.1, F11.2, F11.3, F11.8 and F11.9)
40 (67) 20 (33) 0 (0)
Number of patients involved in the
study that started the consumption
of opioids by legal prescription to
treat any pain
53 (88) 4 (7) 3 (5)
Number of patients with description
in the clinical chart of the pain rating
scale use previous to the first
prescription of opioid
15 (25) 16 (27) 29 (48)
Number of patients suffering clinical
complications (i.e., psychosis) related
to opioid consumption
8 (13) 47 (78) 5 (8)
Number of patients with dependence
to legal opioids perpetuated by
self-medication
54 (90) 2 (3) 4 (7)
Number of patients with dependence
to legal opioids perpetuated also by
diversion consumption for nonmedical
use
9 (15) 32 (53) 19 (32)
Number of patients with description in
the clinical chart of simultaneous use of
psychotropic substance(s) as tobacco,
alcohol and others
19 (32) 27 (45) 14 (23)
Fig. 1 Frequencies of use by type of opioid in patients. The total
number is higher than 60, because all patients could abuse of
opioids using as single drug or mixing it
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related with the acute use of opioids [18], but their role
in the dependence and abuse is still controversial [19].
Recently, Enabah et. al. demonstrated a statistically sig-
nificant higher frequency of alleles CC and CT at site
3435 (rs1045642) of the ABCB1 gene in patients with
dependence [20]. It should be noted that the same single
nucleotide polymorphism in ABCB1 genes was found in
Colombian patients with addictive behavior and addicted
to heroin and cocaine. Then, it seems viable that genet-
ics may contribute to the high frequency of tramadol use
in patients with OAD [21].
The misuse of the opioid medications, is a clear risk
factor for substance use disorder. It has been found that
the patients with both disorders usually report more
pain and impairment and depression disorders as well
[22]. In this study, it was found that 22 patients (37 %)
had associated consumption of other psychotropic sub-
stances, being statistically significant more prominent on
males than in women (P = 0.005).
In our study one of the most striking results was the
opioid use median of 48 months. This is no a minor
point, because the long term use of prescription opioids
is one of the main risk factors to mortality [8].
Almost all patients (≥90 %) met only four DSM-IV
diagnostic criteria for prescription opioid disorder, the
remaining criteria were lesser frequent (≤50 %). Given
this frequency, it could be proposed to divided the
diagnostic criteria in major (common) and minor
(uncommon). During the accomplishment of this trial
the DSM-V was published proposing a severity scale
related with the number of criteria observed in each
patient.
As retrospective study, it has some limitations, as the
lack of control of the use of additional pain medication
in each patient, neither the dose of opioid used or ad-
ministered prior or during the hospitalization.
Finally, this observational study can be considered the
first evidence that OAD is also diagnosed in Colombia.
More prospective and controlled researches, also as na-
tional surveillance are required on this topic and maybe
the enactment of laws promoting new strategies as
abuse-deterrent products.
Conclusion
The prescription opioid disorder is a growing health
problem not only worldwide but also in Colombia,
where currently there are no official statistics of this
problem. It is indispensable to start educating the health
personnel on the correct use of prescription opioids, be-
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